Oh, The Places You'll Go When Trying To Figure Out The Right Dose Of Escitalopram

A thorough psychopharm explainer on why Lexapro (escitalopram) has an unusually low maximum dose yet keeps winning head-to-head SSRI comparisons. Scott traces the low cap to the FDA's overblown-then-never-unbungled torsade-de-pointes scare over parent-drug citalopram, then weighs three explanations: (1) we're overdosing every other SSRI (Furukawa's fixed-dose meta-analysis, sweet spot ~30mg fluoxetine-equivalent) — challenged by Hieronymus on the fixed-dose/no-titration/intention-to-treat confound; (2) Lexapro is genuinely better via allosteric ('ASRI') binding, the 'purely sinister' s-enantiomer stereochemistry; (3) the high-dose evidence (three weak open-label studies + Scott's own titration anecdote). Numerate, honest about uncertainty, and directly actionable for prescribers ('I plan to continue prescribing up to 30-40mg').

Quality 70 · Strong. Strong: a rigorous, well-sourced clinical explainer that turns a messy prescribing question into a usable model, honest about what isn't proven; sits with Scott's other psychopharm explainers (~70).

Claude’s paradigm shift 46 · Moderate. Moderate-notable: assembles and adjudicates competing dosing literatures rather than originating a frame.

Real-world impact 3 · Moderate. Moderate (3): concrete, actionable prescribing guidance from a practicing psychiatrist for a very widely used drug class — real influence on clinical practice within the professional sphere.